论股骨头坏死误诊的现状及分析

股骨头坏死是一种常见的疾病,在30岁至60岁年龄段的人群中较为常见,临床的症状包括疼痛以及髋部不适等,股骨头坏死在早期很难发现,由于没有得到准确的诊断,耽误了最佳的治疗时间和有效的治疗,随着病情的发展,最终将会造成股骨头变形以及塌陷,从而引起骨性关节炎,对髋关节功能的影响是很大的,甚至会丧失髋关节的基本功能。股骨头坏死的病状体征和早期症状存在一定的隐蔽性,因此,造成误诊的情况频繁发生。此外,有些疾病的症状表现为髋关节疼痛,最后反而容易被误诊为股骨头坏死。     

非创伤性股骨头坏死的机制及早期治疗的研究进展

非创伤性股骨头坏死(NONFH)是临床常见的骨科难治性疾病之一,本文就其发病机制和临床治疗研究的相关进展和问题展开综述,旨在进一步提高对NONFH的临床认识和治疗水平。股骨头坏死的机制仍然没有统一的定论,但各种机制最终归于股骨头供血区域血液瘀滞,导致股骨头发生缺血坏死虽然目前还没有一种治疗方法达到理想的治疗效果,髓心减压仍然是应用最为广泛的早期治疗手段,各种改进手术如骨移植、钽棒移植、骨髓干细胞移植和生长因子移植是今后的主要趋势。     

关节镜治疗髋关节疾病的临床研究

目的:研究髋关节镜治疗髋关节疾病的方法、疗效及适应证,探讨髋关节镜在髋关节疾病中的临床价值。方法:研究对象为86例有明显髋关节疼痛的患者,包括股骨头坏死(osteonecrosis,ON)(43%)、盂唇损伤(20%)、退行性关节病变(degenerative joint disease,DJD)(10%)、股骨头骨骺缺血性坏死(Legg-Calve'-Perthes,LCP)(10%)、髋关节游离体(10%)、髋关节疼痛(100%)、机械性损伤(78%)、运动损伤(56%)。对患者采用仰卧位进行髋关节镜检查,使用牵引床,300或700,前外侧入口。观察不同疾病在治疗后的预后结果。结果:所有患者均无并发症,平均随访时间30个月,有60%的患者疼痛症状得到缓解。盂唇(91%,P0.003)或LCP(89%,P0.05)患者疗效较好,而ON和DJD患者疼痛症状缓解较差,改善率仅为40%和44%。在吻合血管游离腓骨移植(free-vascularized fibular graft,FVEG)的患者中有34%在随访期间得到改善(P=0.003)。其中18名患者(21%)进行了全髋关节置换术。结论:髋关节镜手术对于游离体、盂唇损伤、局灶性软骨病变、晚期LCP后遗症患者有良好的治疗效果;对股骨头坏死的治疗效果不佳。     

股骨头缺血坏死介入治疗的临床应用研究

目的:探讨介入治疗股骨头缺血坏死的临床应用价值。方法:采用Seldinger技术对28例患者行超选择股骨头供血动脉插管,动脉造影、溶通治疗。结果:28例患者治疗后髋部疼痛及关节功能障碍均有不同程度的减轻及改善,有效率96.4%;治疗后病变区血管分支增多、增粗;影像随访显示股骨头骨质不同程度修复。结论:介入治疗具有创伤小、并发症低、血管再通率高、临床症状改善明显的优势,能有效的改善股骨头的局部血液循环和髋关节的疼痛、活动功能,应大力推广。     

双极人工股骨头置换治疗老年不稳定股骨粗隆间骨折的临床研究

目的:通过观察我院老年不稳定股骨粗隆间骨折患者临床治疗资料,探讨分析采用双极人工股骨头置换治疗该疾病的临床效果.方法:将我院收治的100例该疾病患者按照手术方法平分为A组与B组两组,分别进行双极人工股骨头置换术与动力髋螺钉手术治疗,对比分析使用两种方法手术时间、出血量情况、术后并发症以及治疗效果等.结果:两组患者经各自手术治疗后,临床症状均有改善,A组患者在手术时间、出血量情况与B组患者相比,差异不显著(P＞0.05),而在术后并发症、髋关节功能对比方面,A组优于B组,差异具有显著性(P＜0.05).结论:采用双极人工股骨头置换手术治疗老年不稳定股骨粗隆间骨折患者,手术并发症少,安全可靠性高.有效改善患者髋关节功能,临床效果显著,值得临床上推广与进一步研究.     

强直性脊柱炎滑膜组织破骨细胞表型、TNF-α及MMP-3的表达及对软骨破坏作用的研究

目的检测破骨细胞表型、基质金属蛋白酶-3及肿瘤坏死因子-α在强直性脊柱炎患者滑膜组织的表达,滑膜单核巨噬细胞与软骨共培养,了解其在强直性脊柱炎软骨破坏中的作用,探讨强直性脊柱炎软骨破坏机制。方法采用酶组织化学技术检测滑膜组织内破骨细胞表型表达,原位杂交技术检测强直性脊柱炎患者滑膜组织内肿瘤坏死因子-α、基质金属蛋白酶-3的表达,Leica Qwin高清晰图像分析系统测定阳性细胞数,强直性脊柱炎滑膜单核巨噬细胞培养并与正常软骨共培养,HE染色及扫描电镜观察软骨的破坏程度。结果破骨表型细胞在滑膜组织内阳性表达,阳性细胞计数与对照组有显著差异（P〈0．01）;肿瘤坏死因子-α、基质金属蛋白酶-3在强直性脊柱炎患者滑膜细胞内有棕黄色颗粒沉着,阳性细胞计数与对照组有显著差异（P〈0．01）;滑膜细胞与正常软骨共培养,HE染色见软骨表面粗糙,有小凹陷,扫描电镜可见软骨表面不定形物质成斑片状,胶原纤维暴露,有断裂,抗肿瘤坏死因子-α可以减轻软骨的破坏程度。结论破骨表型细胞、肿瘤坏死因子-α及基质金属蛋白酶-3是软骨破坏的重要因素,破骨表型细胞通过表达基质金属蛋白酶-3分解软骨基质,进而发挥软骨的破坏作用,抗肿瘤坏死因子-α可以抑制破骨表型细胞对软骨的破坏。     

阿达木单抗的临床应用进展

阿达木单抗是一种抗肿瘤坏死因子α的全人源单克隆抗体,可特异性的结合人肿瘤坏死因子α,阻止其与效应细胞结合而发挥生物学效应,在风湿性关节炎、银屑病、强直性脊柱炎,克罗恩病以及一些自身免疫性疾病的治疗上取得了广泛的应用,本文仅就在这些疾病的临床治疗进展进行综述。     

股骨头坏死行人工髋关节置换的护理干预

目的:分析股骨头坏死行人工髋关节置换的护理干预。方法:2012年6月-2014年6月期间,选取我院收治的53例股骨头坏死行人工髋关节置换术患者为研究对象,给予所有患者针对性护理,对护理资料进行回顾性分析。结果:研究中所有患者在经过有针对性护理之后,恢复良好,并未出现严重并发症,患者住院时间15-35d,平均(23.3±2.1)d。结论:当股骨头坏死患者行人工髋关节置换术后,需对患者的病情进行严密观察,做好患者的心理护理,帮助患者尽早康复。     

成人先天性髋关节发育不良的围手术期护理

成人先天性髋关节发育不良是一种髋臼先天性发育缺陷的疾病,长期发展会形成髋关节半脱位、脱位,最终甚至可能出现股骨头坏死等严重合并症。对于早期患者目前主要采用髋臼旋转截骨手术治疗,而晚期出现股骨头脱位及坏死则只能通过全髋关节置换进行治疗。不论哪种手术方式,围手术期的护理对于患者的健康恢复都有着非常重要的意义。     

成人先天性髋关节发育不良的围手术期护理

成人先天性髋关节发育不良是一种髋臼先天性发育缺陷的疾病,长期发展会形成髋关节半脱位、脱位,最终甚至可能出现股骨头坏死等严重合并症。对于早期患者目前主要采用髋臼旋转截骨手术治疗,而晚期出现股骨头脱位及坏死则只能通过全髋关节置换进行治疗。不论哪种手术方式,围手术期的护理对于患者的健康恢复都有着非常重要的意义。     

人工髋关节置换术在320 例股骨头缺血性坏死中的治疗体会

目的：探讨人工髋关节置换术在治疗股骨头缺血性坏死（ANFH）中的临床疗效。方法：选择2007 年2 月-2011 年2 月我院收 治的320 例（340 髋）股骨头缺血性坏死患者,均采用人工髋关节置换术对患者进行治疗,其中160 例（172 髋）患者应用骨水泥型 假体进行治疗,另外160 例（168）患者采用非骨水泥型假体进行治疗。采用Harris评分对患者手术前后的髋关节功能情况进行评 价,并比较骨水泥治疗组和非骨水泥治疗组的临床疗效。结果：患者均获得随访,随访时间为3～18 个月。全部患者手术后的 Harris评分明显高于手术前,差异有统计学意义（P<0.05）。骨水泥治疗组和非骨水泥治疗组在术后出血量、术后Harris 评分及住 院时间方面的差异无统计学意义（P>0.05）,但非骨水泥治疗组的并发症发生率明显低于骨水泥治疗组（P<0.05）。结论：采用人工 髋关节置换术治疗ANFH疗效显著,能明显改善患者的生活质量,骨水泥型假体与非骨水泥型假体的治疗效果相当,应根据患者 的具体情况进行合理的选择。     

Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future

Structural changes of bone and cartilage are a hallmark of inflammatory joint diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). Despite certain similarities - in particular, inflammation as the driving force for structural changes - the three major inflammatory joint diseases show considerably different pathologies. Whereas RA primarily results in bone and cartilage resorption, PsA combines destructive elements with anabolic bone responses, and AS is the prototype of a hyper-responsive joint disease associated with substantial bone and cartilage apposition. In the present review we summarize the clinical picture and pathophysiologic processes of bone and cartilage damage in RA, PsA, and AS, we describe the key insights obtained from the introduction of TNF blockade, and we discuss the future challenges and frontiers of structural damage in arthritis.     

Expanding the armamentarium for the spondyloarthropathies

Ankylosing spondylitis (AS) is a member of the family of spondyloarthropathies, which are inflammatory arthritides largely involving the axial skeleton and commonly accompanied by peripheral arthritis. Genetic factors, particularly the presence of HLA-B27, are major contributors to the susceptibility for AS. Despite some therapeutic advances, the treatment options for patients with AS and related disorders have been limited. Several lines of evidence have led to the hypothesis that patients with AS might benefit from treatment with tumor necrosis factor (TNF). Specifically, TNF concentrations are known to be significantly elevated in the synovium of patients with rheumatoid arthritis (RA), in the inflamed gut of patients with inflammatory bowel disease, and in the inflamed sacroiliac joints of patients with AS. The anti-TNF agents have been shown to be of benefit in, and currently have indications for, RA (etanercept, infliximab, adalimumab), Crohn's disease (infliximab), and psoriatic arthritis (etanercept). Because the spondyloarthropathies share pathogenetic mechanisms with the above-specified disease states, studies have been conducted to evaluate the effectiveness of anti-TNF agents in several disorders, including AS. Data from clinical trials so far with infliximab and etanercept show that patients with AS and related disorders achieve significant improvement in clinical signs and symptoms based on validated outcomes measures. Computed tomography and magnetic resonance imaging (MRI) can facilitate the early diagnosis of AS. Studies with infliximab using MRI together with updated scoring methods demonstrated significant decreases in associated spinal inflammation. TNF antagonist therapy is well tolerated in patients with AS, with a side effect profile consistent with the prior experience of patients with RA.     

Infliximab: 12 years of experience

Rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) are immune-mediated conditions that share an inflammatory mechanism fuelled by excessive cytokines, particularly TNF. Control of inflammation and rapid suppression of cytokines are important in treating these diseases. With this understanding and the corresponding advent of TNF inhibitors, RA patients, AS patients and PsA patients have found more choices than ever before and have greater hope of sustained relief. As a widely used TNF inhibitor, infliximab has a deep and established record of efficacy and safety data. Extensive evidence - from randomised controlled clinical trials, large registries and postmarketing surveillance studies - shows that infliximab effectively treats the signs and symptoms, provides rapid and prolonged suppression of inflammation, prevents radiologically observable disease progression and offers an acceptable safety profile in RA, AS and PsA. In very recent studies, investigators have observed drug-free remission in some patients. Additionally, infliximab may interfere with rapidly progressing disease in RA by early addition to methotrexate in patients with signs of an aggressive course. Finally, infliximab has been shown to reduce PsA clinical manifestations such as nail involvement. With our current understanding, substantial data and increasing confidence regarding use in practice, infliximab can be considered a well-known drug in our continued campaign against inflammatory rheumatic diseases.     

Frequency of Lost to Follow-Up and Associated Factors for Patients with Rheumatic Diseases

Objective

To determine the frequency of lost to follow-up (LTFU) in the setting of usual care for outpatients with rheumatic diseases including RA, SLE, AS, and Ps/PsA, to explore the associated demographic factors, and to investigate the reasons for being LTFU from the original medical care.

Methods

Patients registered between May 2011 and January 2014 at the rheumatology outpatient department of a medical center were included. Those who did not attend their scheduled appointment were defined as LTFU. Univariate and multivariate logistic regression were used to analyze the factors for being LTFU.

Results

A total of 781 patients were enrolled, including 406 patients with RA, 174 with SLE, 136 with AS, and 65 with Ps/PsA. The frequency of LTFU was 23.9%, 25.9%, 35.3%, and 35.4%, respectively. The frequency of LTFU was significantly different between the four rheumatic diseases (p = 0.028). In multivariate logistic regression analysis, an older age increased being LTFU in the patients with RA (OR 1.02; 95% CI 1.00–1.04; p = 0.033), but reduced being LTFU in those with Ps/PsA (OR 0.96; 95% CI 0.92–0.99; p = 0.021). Female patients with SLE and Ps/PsA were more likely to be LTFU, although this did not reach statistical significance (p = 0.056 and 0.071, respectively). The most common reason for being LTFU was moving to other district hospitals from the original medical center due to convenience for the patients with RA and SLE, and stopping medication due to minimal symptoms for the patients with AS and Ps/PsA.

Conclusions

The frequency of LTFU in patients with rheumatic diseases is high. Associated demographic factors included older age in RA, female gender in SLE and Ps/PsA, and younger age in Ps/PsA, with various reasons for being LTFU. Recognizing these associated factors and reasons for being LTFU may help to improve the attendance of patients and the quality of medical care.     

Autosomal dominant avascular necrosis of femoral head in two Taiwanese pedigrees and linkage to chromosome 12q13

Avascular necrosis of the femoral head (ANFH) is a debilitating disease that commonly leads to destruction of the hip joint in adults. The etiology of ANFH is unknown, but previous studies have indicated that heritable thrombophilia (increased tendency to form thrombi) and hypofibrinolysis (reduced ability to lyse thrombi), alcohol intake, and steroid use are risk factors for ANFH. We recently identified two families with ANFH showing autosomal dominant inheritance. By applying linkage analysis to a four-generation pedigree, we excluded linkage between the family and three genes related to thrombophilia and hypofibrinolysis: protein C, protein S, and plasminogen activator inhibitor. Furthermore, by a genomewide scan, a significant two-point LOD score of 3.45 (recombination fraction [theta] = 0) was obtained between the family with ANFH and marker D12S85 on chromosome 12. High-resolution mapping was conducted in a second family with ANFH and replicated the linkage to D12S368 (pedigree I: LOD score 2.47, theta = 0.05; pedigree II: LOD score 2.81, theta = 0.10). When an age-dependent-penetrance model was applied, the combined multipoint LOD score was 6.43 between D12S1663 and D12S85. Thus, we mapped the candidate gene for autosomal dominant ANFH to a 15-cM region between D12S1663 and D12S1632 on chromosome 12q13.     

Detection of multiple autoantibodies in patients with ankylosing spondylitis using nucleic acid programmable protein arrays

Ankylosing spondylitis (AS) is a common, inflammatory rheumatic disease that primarily affects the axial skeleton and is associated with sacroiliitis, uveitis, and enthesitis. Unlike other autoimmune rheumatic diseases, such as rheumatoid arthritis or systemic lupus erythematosus, autoantibodies have not yet been reported to be a feature of AS. We therefore wished to determine whether plasma from patients with AS contained autoantibodies and, if so, characterize and quantify this response in comparison to patients with rheumatoid arthritis (RA) and healthy controls. Two high density nucleic acid programmable protein arrays expressing a total of 3498 proteins were screened with plasma from 25 patients with AS, 17 with RA, and 25 healthy controls. Autoantigens identified were subjected to Ingenuity Pathway Analysis to determine the patterns of signaling cascades or tissue origin. 44% of patients with ankylosing spondylitis demonstrated a broad autoantibody response, as compared with 33% of patients with RA and only 8% of healthy controls. Individuals with AS demonstrated autoantibody responses to shared autoantigens, and 60% of autoantigens identified in the AS cohort were restricted to that group. The autoantibody responses in the AS patients were targeted toward connective, skeletal, and muscular tissue, unlike those of RA patients or healthy controls. Thus, patients with AS show evidence of systemic humoral autoimmunity and multispecific autoantibody production. Nucleic acid programmable protein arrays constitute a powerful tool to study autoimmune diseases.     

The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases

In this study, we compare the health-related quality of life (HRQoL) of patients with moderate-to-severe rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS), and study the effect of treatment with infliximab on the HRQoL of patients with these diseases. Short Form Health Survey-36 (SF-36) data from the placebo-controlled phases of 4 studies of infliximab in patients with inflammatory rheumatic diseases (n = 1990) were evaluated. Data came from the Anti-TNF Trial in Rheumatoid Arthritis with Concomitant Therapy (ATTRACT) (n = 428), the Safety Trial for Rheumatoid Arthritis with REMICADE Therapy (START) (n = 1083), the Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy (ASSERT) (n = 279), and the Infliximab Multinational Psoriatic Arthritis Clinical Trial II (IMPACT II) (n = 200). SF-36 assessments were made at weeks 0, 10, 30, and 54 in ATTRACT, weeks 0, 6, and 22 in START, weeks 0, 12, and 24 in ASSERT, and weeks 0 and 14 in IMPACT II. All patient populations had significantly impaired physical aspects of HRQoL at baseline relative to the general population of the United States, and the magnitude of impairment was similar across the diseases. Mean baseline physical component summary scores were 29 in the RA cohort, 32 in the PsA cohort, and 29 in the AS cohort. In all 3 diseases, patients who received infliximab showed significant improvement in physical component summary scores compared with those who received placebo. The magnitude of the difference of improvement (effect size, 95%CI) between infliximab and placebo groups was similar in the AS (10.1, 9.2–11.0), PsA (8.6, 7.8–9.4), and RA (10.1, 9.2–11.0) cohorts. Patients with RA and those with PsA treated with infliximab also showed greater improvement in the mental component summary score than those in the placebo group with an effect size of 4.6 (4.2–5.1) in RA and 2.7 (2.4–3.1) in PsA. Patients in large randomized controlled studies of infliximab in RA, PsA, and AS had similar impairment in physical aspects of HRQoL at baseline and showed significantly greater improvement in HRQoL after treatment with infliximab.     

人工髋关节置换术在320例股骨头缺血性坏死中的治疗体会

目的：探讨人工髋关节置换术在治疗股骨头缺血性坏死（ANFH）中的临床疗效。方法：选择2007年2月-2011年2月我院收治的320例（340髋）股骨头缺血性坏死患者,均采用人工髋关节置换术对患者进行治疗,其中160例（172髋）患者应用骨水泥型假体进行治疗,另外160例（168）患者采用非骨水泥型假体进行治疗。采用Harris评分对患者手术前后的髋关节功能情况进行评价,并比较骨水泥治疗组和非骨水泥治疗组的临床疗效。结果：患者均获得随访,随访时间为3～18个月。全部患者手术后的Harris评分明显高于手术前,差异有统计学意义（P〈0．05）。骨水泥治疗组和非骨水泥治疗组在术后出血量、术后Harris评分及住院时间方面的差异无统计学意义（P〉0．05）,但非骨水泥治疗组的并发症发生率明显低于骨水泥治疗组（P〈0．05）。结论：采用人工髋关节置换术治疗ANFH疗效显著,能明显改善患者的生活质量,骨水泥型假体与非骨水泥型假体的治疗效果相当,应根据患者的具体情况进行合理的选择。